Search hospitals > Minnesota > Minneapolis
Fairview Southdale Hospital
Claim this profileMinneapolis, Minnesota 55435
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
555 reported clinical trials
15 medical researchers
Summary
Fairview Southdale Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Fairview Southdale Hospital is involved with conducting 555 clinical trials across 569 conditions. There are 15 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
David M. KingRegions Hospital7 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
91 reported clinical trials
154 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital4 years of reported clinical research
Expert in Cancer
Expert in Tumors
59 reported clinical trials
107 drugs studied
Yan JiRegions Hospital1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
29 reported clinical trials
72 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park5 years of reported clinical research
Studies Cancer
Studies Tumors
14 reported clinical trials
19 drugs studied
Clinical Trials running at Fairview Southdale Hospital
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Gastric Cancer
Multiple Myeloma
Esophageal Cancer
Anal Cancer
Tumors
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Fairview Southdale Hospital?
Fairview Southdale Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Fairview Southdale Hospital is involved with conducting 555 clinical trials across 569 conditions. There are 15 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Fairview Southdale Hospital located?
**Directions to Fairview Southdale Hospital, Minneapolis:**
- Take Interstate 35W south to Highway 62 (Crosstown).
- Follow Highway 62 west to France Ave and turn left.
- Continue for one block to 65th St.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Fairview Southdale Hospital, visit [Fairview Financial Assistance](http://www.fairview.org/billing/fairview-financial-assistance) for policy details and application forms. For assistance or inquiries, contact the Customer Service Center at 612-672-6724. For insurance-related questions and bill payment options (online, by phone, by mail, or in person), refer to the Bill Pay & Financial Resources page.
What insurance does Fairview Southdale Hospital accept?
Fairview Southdale Hospital accepts a wide range of insurance plans, including the 2023 Fairview Medical Plans, which provide local coverage in the 11-county Twin Cities metro area and nationwide coverage. M Health Fairview providers are in-network for many insurance plans. UCare Individual & Family Plans with M Health Fairview feature cost-effective options with access to popular providers in the Twin Cities.
What awards or recognition has Fairview Southdale Hospital received?
Fairview Southdale Hospital, located in Minneapolis, Minnesota, is renowned for its emergency heart attack program and advanced imaging services. It has been named the top hospital in the Twin Cities metro for cardiology and coronary intervention. As part of the M Health Fairview system, it provides access to the University of Minnesota Medical Center's cutting-edge medical research and specialties.